0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Short-Term Hormone Therapy Suspension and Mammography Recall: A Randomized Trial

Diana S.M. Buist, PhD, MPH; Melissa L. Anderson, MS; Susan D. Reed, MD, MS, MPH; Erin J. Aiello Bowles, MPH; E. Dawn Fitzgibbons, MPH; Juleann C. Gandara, MD; Deborah Seger, BA; and Katherine M. Newton, PhD
[+] Article and Author Information

ClinicalTrials.gov registration number:NCT00117663.


From Group Health Center for Health Studies, University of Washington, and Group Health Permanente, Seattle, Washington.


Note: The study team had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Acknowledgment: The authors thank Tammy Dodd, Linda Palmer, and Melissa Rabelhofer, as well as members of their advisory board: Hermien Watkins, Paula Hoffman, Deb Schiro, and Margrit Schubiger; members of the Data Safety and Monitoring Board: Susan Heckbert, Ben Anderson, Mary Anne Rossing, Robert D. Rosenberg, and Thomas Lumley; and Elizabeth Lin, the medical monitor. The authors also thank Robert Karl, Donna White, and Jo Ellen Callahan for their support for implementing this trial at Group Health. Finally, the authors thank Stephen Taplin, for his collaboration in getting this study funded when he was an investigator at Group Health Cooperative, and Rebecca Hughes for her editorial assistance.

Grant Support: The READ Trial was funded by the Department of Defense (DAMD17-03-1-0447). Study participants were recruited from the Group Health Breast Cancer Screening Program, which is funded by the National Cancer Institute (U01CA63731).

Potential Financial Conflicts of Interest: None disclosed.

Reproducible Research Statement:Study protocol: Available from Dr. Buist (e-mail, buist.d@ghc.org). Statistical code: Available from Ms. Anderson (e-mail, Anderson.Melissa@ghc.org). Data set: Not available.

Requests for Single Reprints: Diana S.M. Buist, PhD, MPH, Group Health Center for Health Studies, 1730 Minor Avenue, Suite 1600, Seattle, WA 98101-1448; e-mail, buist.d@ghc.org.

Current Author Addresses: Drs. Buist and Newton, Ms. Anderson, Ms. Aiello Bowles, Ms. Fitzgibbons, and Ms. Seger: Group Health Center for Health Studies, 1730 Minor Avenue, Suite 1600, Seattle, WA 98101-1448.

Dr. Reed: Obstetrics and Gynecology, Harborview Medical Center, Box 359865, Seattle, WA 98104-2499.

Dr. Gandara: Group Health Family Health Center, 125 16th Avenue East, Seattle, WA 98112.

Author Contributions: Conception and design: D.S.M. Buist, K.M. Newton.

Analysis and interpretation of the data: D.S.M. Buist, M.L. Anderson, S.D. Reed, E.J. Aiello Bowles, K.M. Newton.

Drafting of the article: D.S.M. Buist, M.L. Anderson, S.D. Reed, D. Seger.

Critical revision of the article for important intellectual content: D.S.M. Buist, M.L. Anderson, S.D. Reed, E.J. Aiello Bowles, K.M. Newton.

Final approval of the article: D.S.M. Buist, M.L. Anderson, S.D. Reed, E.J. Aiello Bowles, E.D. Fitzgibbons, J.C. Gandara, K.M. Newton.

Provision of study materials or patients: D.S.M. Buist, E.D. Fitzgibbons, J.C. Gandara.

Statistical expertise: D.S.M. Buist, M.L. Anderson.

Obtaining of funding: D.S.M. Buist.

Administrative, technical, or logistic support: D.S.M. Buist, E.D. Fitzgibbons, J.C. Gandara, D. Seger.

Collection and assembly of data: D.S.M. Buist, E.J. Aiello Bowles, E.D. Fitzgibbons, J.C. Gandara, D. Seger.


Ann Intern Med. 2009;150(11):752-765. doi:10.7326/0003-4819-150-11-200906020-00003
Text Size: A A A

Background: Without population-based evidence, some clinicians recommend short-term suspension of hormone therapy to improve the performance of mammography. Hormone therapy increases breast density, and abnormal screening mammograms are more common among women with denser breasts and among women using hormone therapy.

Objective: To test whether 1 to 2 months of hormone therapy suspension before screening mammography decreases additional mammographic imaging (recall) in women age 45 to 80 years.

Design: 3-group randomized, controlled trial.

Setting: Integrated health plan in western Washington from 2004 to 2007.

Patients: 1704 women age 45 to 80 years who used hormone therapy at their most recent screening (index) mammography, were due for screening (study) mammography, and were still using hormone therapy.

Intervention: Block random assignment (by breast density and hormone therapy type) to no hormone therapy suspension (n = 567) or suspension for 1 month (n = 570) or 2 months (n = 567) before study mammography. One blinded expert radiologist interpreted all mammograms.

Measurements: Recall was the primary outcome, and change in mammographic breast density (percentage and dense area) between the index and study mammograms was the secondary outcome.

Results: Mammography recall rates were 11.3% (61 of 542 women in the no-suspension group), 12.3% (50 of 478 women in the 1-month suspension group), and 9.8% (44 of 451 women in the 2-month suspension group). No subgroups were identified in which brief suspension of hormone therapy resulted in decreased mammography recall. With suspension, decreases in percentage of breast density were orderly and statistically significant: 0.1% (no-suspension group), −0.9% (1-month suspension group), and −1.5% (2-month suspension group). Similar ordered decreases were observed for dense area. Women in the suspension groups experienced increased menopause symptoms.

Limitations: Results can only be generalized to women age 45 to 80 years who have used hormone therapy for at least 1 year and will consider short-term suspension; most eligible women (61%) declined participation. Mammography recall was determined by 1 expert radiologist.

Conclusion: Brief hormone therapy suspension was associated with small changes in breast density and did not affect recall rates. No evidence supports short-term hormone therapy suspension before mammography.

Primary Funding Source: U.S. Department of Defense and the National Cancer Institute.

Figures

Grahic Jump Location
Figure 1.
Recruitment for the READ (Radiological Evaluation and Breast Density) Study.

HT = hormone therapy.

Grahic Jump Location
Grahic Jump Location
Figure 2.
Difference between index and study mammogram in mean percentage of breast density and dense area.

BMI = body mass index; E = estrogen; E + P = estrogen plus progestin; HT = hormone therapy.

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Hormone Therapy Suspension and Mammography in the Women's Health Initiative Clinical Trials
Posted on June 30, 2009
Rowan T Chlebowski
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Conflict of Interest: None Declared

The Women's Health Initiative (WHI) randomized clinical trials evaluating hormonal therapy have previously published findings which address and expand those recently published by Buist and colleagues (1). In the WHI clinical trial evaluating estrogen plus progestin, 16,608 postmenopausal women were randomized to receive combined hormone therapy or placebo. When the trial intervention was ended, women were informed by letter to stop study pills that day and almost all did. Women in the combined estrogen plus progestin group had significantly more mammograms requiring a physician-directed intervention (short interval follow-up suggested, suspicious abnormalities, and those highly suggestive of malignancy) during the intervention (2) and throughout first post-intervention year but not thereafter (P=0.005) (3) Thus, somewhat over one year is required for improvement in mammography performance after stopping combined estrogen plus progestin use.

In an ancillary study in the same WHI clinical trial, the association between combined estrogen plus progestin use and mammographic density was examined in a randomly identified sub-sample of trial participants. In this randomized population of 1,413 postmenopausal women, there was a statistically significant 6.0% increase in density after 1 year and a 4.9% increase at 2 years with estrogen plus progestin use findings (4) The magnitude of the increase in breast density was somewhat higher than in the cited PEPI trial. Taken together, the PEPI and WHI findings suggest that changes in breast density associated with combined hormone therapy use are substantially greater in magnitude than those observed during a menstrual cycle.

Finally, in the WHI randomized clinical trial evaluating estrogen alone in postmenopausal women with prior hysterectomy which randomized 10,739 participants, mammograms suspicious or highly suggestive of malignancy were not increased in the estrogen alone hormone groups (5) a finding which was different from that reported in the WHI combined hormone therapy trial where an increase in abnormal mammograms was seen with estrogen plus progestin (2). Thus, differences in mammography recall rates between women receiving estrogen alone compared to combined estrogen plus progestin use would be anticipated. Awareness of these findings from the WHI randomized trials should put those of Buist and colleagues in a more complete clinical context.

References:

1. Buist DSM, Anderson ML, Reed SD, et al. Short-term hormone therapy suspension and mammography recall. A randomized trial. Ann Intern Med 2009;150:752-765.

2. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003;289:3243 -53.

3. Chlebowski RT, Anderson GL, Petinger M, et al. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med 2008;168:370-7.

4. McTiernan A, Martin C, Peck J, et al. Estrogen and progestin influence on mammogram density in healthy postmenopausal women in the Women's Health Initiative Randomized Trial. J Natl Cancer Inst. 97(8):684 -91, 2005.

5. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography in postmenopausal women with hysterectomy: The Women's Health Initiative randomized trial JAMA 242:1048-63, 2006.

Conflict of Interest:

None declared

Submit a Comment

Summary for Patients

Mammogram Recall Rates After Stopping Hormone Therapy

The summary below is from the full report titled “Short-Term Hormone Therapy Suspension and Mammography Recall. A Randomized Trial.” It is in the 2 June 2009 issue of Annals of Internal Medicine (volume 150, pages 752-765). The authors are D.S.M. Buist, M.L. Anderson, S.D. Reed, E.J. Aiello Bowles, E.D. Fitzgibbons, J.C. Gandara, D. Seger, and K.M. Newton.

Read More...

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)